Retinal inflammation: Uveitis/uveoretinitis

Neuromethods

Volumn 46, Issue , 2010, Pages 207-225

  Horai, Reiko ^a   Caspi, Rachel R ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

Autoimmune disease; EAU; Experimental autoimmune uveitis; T lymphocytes; Tolerance; Uveitis; Uveoretinitis

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; DACLIZUMAB; RAPAMYCIN; TACROLIMUS;

BEHCET DISEASE; CHORIORETINOPATHY; CLINICAL FEATURE; GENETIC ASSOCIATION; HOMEOSTASIS; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RETINITIS; RETINOPATHY; REVIEW; SARCOIDOSIS; SYMPATHETIC OPHTHALMIA; UVEITIS; UVEORETINITIS; VOGT KOYANAGI SYNDROME;

ANIMALIA;

EID: 74549159664     PISSN: 08932336     EISSN: 19406045     Source Type: Book Series    
DOI: 10.1007/978-1-60761-541-5_11     Document Type: Review

References (61)

1. Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111(3):491-500 discussion
2. Nussenblatt RB, Whitcup SM (2004) Uveitis: fundamentals and clinical practice, 3rd edn. Mosby (Elsevier), Philadelphia, PA
3. Pennesi G, Caspi RR (2002) Genetic control of susceptibility in clinical and experimental uveitis. Int Rev Immunol 21(2-3):67-88
4. Caspi RR (2006) Animal models of autoimmune and immune-mediated uveitis. Drug Discov Today Dis Models 3:3-10 (http:// dxdoiorg/101016/jddmec200605006)
5. Arayssi T, Hamdan A (2004) New insights into the pathogenesis and therapy of Behcet's disease. Curr Opin Pharmacol 4(2):183-188
6. Gery I, Nussenblatt RB, Chan CC, Caspi RR (2002) Autoimmune diseases of the eye. The molecular pathology of autoimmune diseases, 2nd edn. Taylor and Francis, New York, NY, pp 978-998
7. Damico FM, Kiss S, Young LH (2005) Vogt- Koyanagi-Harada disease. Semin Ophthalmol 20(3):183-190
8. Monnet D, Brezin AP (2006) Birdshot chorioretinopathy. Curr Opin Ophthalmol 17(6):545-550
9. Ding X, Patel M, Chan CC (2009) Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 28(1):1-18
10. Agarwal RK, Caspi RR (2004) Rodent models of experimental autoimmune uveitis. Methods Mol Med 102:395-419
11. Lai JC, Fukushima A, Wawrousek EF et al (1998) Immunotolerance against a foreign antigen transgenically expressed in the lens. Invest Ophthalmol Vis Sci 39(11): 2049-2057
12. Gregerson DS, Torseth JW, McPherson SW, Roberts JP, Shinohara T, Zack DJ (1999) Retinal expression of a neo-self antigen, betagalactosidase, is not tolerogenic and creates a target for autoimmune uveoretinitis. J Immunol 163(2):1073-1080
13. Ham DI, Kim SJ, Chen J et al (2004) Central immunotolerance in transgenic mice expressing a foreign antigen under control of the rhodopsin promoter. Invest Ophthalmol Vis Sci 45(3):857-862
14. Lambe T, Leung JC, Ferry H et al (2007) Limited peripheral T cell anergy predisposes to retinal autoimmunity. J Immunol 178(7):4276-4283
15. Terrada C, Fisson S, De Kozak Y et al (2006) Regulatory T cells control uveoretinitis induced by pathogenic Th1 cells reacting to a specific retinal neoantigen. J Immunol 176(12):7171-7179
16. Caspi RR, Chan CC, Leake WC, Higuchi M, Wiggert B, Chader GJ (1990) Experimental autoimmune uveoretinitis in mice. Induction by a single eliciting event and dependence on quantitative parameters of immunization. J Autoimmun 3(3):237-246
17. Xu H, Koch P, Chen M, Lau A, Reid DM, Forrester JV (2008) A clinical grading system for retinal inflammation in the chronic model of experimental autoimmune uveoretinitis using digital fundus images. Exp Eye Res 87(4):319-326
18. Copland DA, Wertheim MS, Armitage WJ, Nicholson LB, Raveney BJ, Dick AD (2008) The clinical time-course of experimental autoimmune uveoretinitis using topical endoscopic fundal imaging with histologic and cellular infiltrate correlation. Invest Ophthalmol Vis Sci 49(12):5458-5465
19. Taneja V, David CS (1999) HLA class II transgenic mice as models of human diseases. Immunol Rev 169:67-79
20. Pennesi G, Mattapallil MJ, Sun SH et al (2003) A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice. J Clin Invest 111(8):1171-1180
21. de Smet MD, Bitar G, Roberge FG, Gery I, Nussenblatt RB (1993) Human S-antigen: presence of multiple immunogenic and immunopathogenic sites in the Lewis rat. J Autoimmun 6(5):587-599 (Pubitemid 23334529)
22. Lai JC, Lobanoff MC, Fukushima A et al (1999) Uveitis induced by lymphocytes sensitized against a transgenically expressed lens protein. Invest Ophthalmol Vis Sci 40(11):2735-2739
23. Tang J, Zhu W, Silver PB, Su SB, Chan CC, Caspi RR (2007) Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signature and is driven by unique effector mechanisms: initial encounter with autoantigen defines disease phenotype. J Immunol 178(9):5578-5587
24. Szpak Y, Vieville JC, Tabary T et al (2001) Spontaneous retinopathy in HLA-A29 transgenic mice. Proc Natl Acad Sci U S A 98(5):2572-2576
25. de Kozak Y, Camelo S, Pla M (2008) Pathological aspects of spontaneous uveitis and retinopathy in HLA-A29 transgenic mice and in animal models of retinal autoimmunity: relevance to human pathologies. Ophthalmic Res 40(3-4):175-180
26. Anderson MS, Venanzi ES, Klein L et al (2002) Projection of an immunological self shadow within the thymus by the aire protein. Science 298(5597):1395-1401
27. DeVoss J, Hou Y, Johannes K et al (2006) Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med 203(12):2727-2735
28. Ichikawa T, Taguchi O, Takahashi T et al (1991) Spontaneous development of autoimmune uveoretinitis in nude mice following reconstitution with embryonic rat thymus. Clin Exp Immunol 86(1):112-117
29. Zhang M, Vacchio MS, Vistica BP et al (2003) T cell tolerance to a neo-self antigen expressed by thymic epithelial cells: the soluble form is more effective than the membrane-bound form. J Immunol 170(8):3954-3962
30. McPherson SW, Heuss ND, Gregerson DS (2009) Lymphopenia-induced proliferation is a potent activator for CD4+ T cell-mediated autoimmune disease in the retina. J Immunol 182(2):969-979
31. Avichezer D, Grajewski RS, Chan CC et al (2003) An immunologically privileged retinal antigen elicits tolerance: major role for central selection mechanisms. J Exp Med 198(11): 1665-1676
32. Grajewski RS, Silver PB, Agarwal RK et al (2006) Endogenous IRBP can be dispensable for generation of natural CD4+CD25+ regulatory T cells that protect from IRBPinduced retinal autoimmunity. J Exp Med 203(4):851-856
33. Takase H, Yu CR, Mahdi RM et al (2005) Thymic expression of peripheral tissue antigens in humans: a remarkable variability among individuals. Int Immunol 17(8): 1131-1140
34. Caspi RR (2006) Ocular autoimmunity: the price of privilege? Immunol Rev 213:23-35
35. McPherson SW, Roberts JP, Gregerson DS (1999) Systemic expression of rat soluble retinal antigen induces resistance to experimental autoimmune uveoretinitis. J Immunol 163(8):4269-4276
36. Xu H, Wawrousek EF, Redmond TM et al (2000) Transgenic expression of an immunologically privileged retinal antigen extraocularly enhances self tolerance and abrogates susceptibility to autoimmune uveitis. Eur J Immunol 30(1):272-278
37. Gregerson DS, Heuss ND, Lehmann U, McPherson SW (2008) Evidence for extrathymic generation of regulatory T cells specific for a retinal antigen. Ophthalmic Res 40(3-4):154-159
38. Amadi-Obi A, Yu CR, Liu X et al (2007) TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13(6):711-718
39. Chi W, Yang P, Li B et al (2007) IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol 119(5):1218-1224
40. Chi W, Zhu X, Yang P et al (2008) Upregulated IL-23 and IL-17 in behcet patients with active uveitis. Invest Ophthalmol Vis Sci 49(7):3058-3064
41. Luger D, Silver PB, Tang J et al (2008) Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 205(4):799-810
42. Chen L, Yang P, Zhou H et al (2008) Decreased frequency and diminished function of CD4+CD25high regulatory T cells are associated with active uveitis in patients with Vogt-Koyanagi-Harada syndrome. Invest Ophthalmol Vis Sci 49(8):3475-3482
43. Ke Y, Jiang G, Sun D, Kaplan HJ, Shao H (2008) Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis. Invest Ophthalmol Vis Sci 49(9):3999-4007
44. Han G, Shao H, Peng Y et al (2007) Suppressor role of rat CD8+CD45RClow T cells in experimental autoimmune uveitis (EAU). J Neuroimmunol 183(1-2):81-88
45. Caspi RR, Grubbs BG, Chan CC, Chader GJ, Wiggert B (1992) Genetic control of susceptibility to experimental autoimmune uveoretinitis in the mouse model. Concomitant regulation by MHC and non-MHC genes. J Immunol 148(8):2384-2389
46. Caspi RR, Silver PB, Chan CC et al (1996) Genetic susceptibility to experimental autoimmune uveoretinitis in the rat is associated with an elevated Th1 response. J Immunol 157(6):2668-2675
47. Sun B, Sun SH, Chan CC, Wiggert B, Caspi RR (1999) Autoimmunity to a pathogenic retinal antigen begins as a balanced cytokine response that polarizes towards type 1 in a disease-susceptible and towards type 2 in a disease-resistant genotype. Int Immunol 11(8):1307-1312
48. Nussenblatt RB, Dinning WJ, Fujikawa LS, Chan CC, Palestine AG (1985) Local cyclosporine therapy for experimental autoimmune uveitis in rats. Arch Ophthalmol 103(10):1559-1562
49. Nussenblatt RB, Fortin E, Schiffman R et al (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 96(13): 7462-7466
50. Nussenblatt RB (2002) Bench to bedside: new approaches to the immunotherapy of uveitic disease. Int Rev Immunol 21(2-3):273-289
51. Yeh S, Wroblewski K, Buggage R et al (2008) High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun 31(2):91-97
52. Agarwal RK, Kang Y, Zambidis E, Scott DW, Chan CC, Caspi RR (2000) Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest 106(2):245-252
53. Silver PB, Agarwal RK, Su SB et al (2007) Hydrodynamic vaccination with DNA encoding an immunologically privileged retinal antigen protects from autoimmunity through induction of regulatory T cells. J Immunol 179(8):5146-5158
54. Caspi RR (2008) Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol 8(12):970-976
55. Smith JR, Verwaerde C, Rolling F et al (2005) Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis. Hum Gene Ther 16(9):1037-1046
56. Bejjani RA, Andrieu C, Bloquel C, Berdugo M, BenEzra D, Behar-Cohen F (2007) Electrically assisted ocular gene therapy. Surv Ophthalmol 52(2):196-208
57. Karabekian Z, Lytton SD, Silver PB, Sergeev YV, Schneck JP, Caspi RR (2005) Antigen/ MHC class II/Ig dimers for study of uveitogenic T cells: IRBP p161-180 presented by both IA and IE molecules. Invest Ophthalmol Vis Sci 46(10):3769-3776
58. Buckner JH, Holzer U, Novak EJ, Reijonen H, Kwok WW, Nepom GT (2002) Defining antigen-specific responses with human MHC class II tetramers. J Allergy Clin Immunol 110(2):199-208
59. Cortes LM, Mattapallil MJ, Silver PB et al (2008) Repertoire analysis and new pathogenic epitopes of IRBP in C57BL/6 (H-2b) and B10.RIII (H-2r) mice. Invest Ophthalmol Vis Sci 49(5):1946-1956
60. Silver PB, Rizzo LV, Chan CC, Donoso LA, Wiggert B, Caspi RR (1995) Identification of a major pathogenic epitope in the human IRBP molecule recognized by mice of the H-2r haplotype. Invest Ophthalmol Vis Sci 36(5):946-954
61. Namba K, Ogasawara K, Kitaichi N et al (1998) Identification of a peptide inducing experimental autoimmune uveoretinitis (EAU) in H-2Ak-carrying mice. Clin Exp Immunol 111(2):442-449